News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IsoRay Medical, Inc. (ISRY) Announces It Has Provided Seeds to Canada for Research Initiatives to Expand the Use of Cesium-131 for New Cancer Applications


1/25/2010 10:21:49 AM

RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (AMEX: ISR) announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES